Related Experiment Video
Updated: Sep 9, 2025

06:37
Immunolabelling Myofiber Degeneration in Muscle Biopsies
Published on: December 5, 2019
9.0K
Focal Neurogenic Muscle Hypertrophy and Focal Neurogenic Myositis
Kevin J Felice1, Charles H Whitaker1, William J Pesce2
1Department of Neuromuscular Medicine, Hospital for Special Care, New Britain, Connecticut, USA.
Muscle & Nerve
|August 29, 2025
Summary
Focal neurogenic muscle hypertrophy (F-NMH) is a rare, benign reaction to peripheral nerve injury, often presenting as calf muscle enlargement. Most patients improve, with botulinum toxin and prednisone showing efficacy.
Area of Science:
- Neurology
- Muscle Physiology
- Pathology
Background:
- Focal neurogenic muscle hypertrophy (F-NMH) and focal myositis (F-NM) describe paradoxical skeletal muscle changes after peripheral motor axon injury.
- Over 100 cases reported since 1978, indicating a rare but documented phenomenon.
Purpose of the Study:
- To review clinicopathological data of F-NMH and F-NM patients.
- To analyze clinical presentation, electrodiagnostic findings, imaging, histopathology, and treatment outcomes.
Main Methods:
- Retrospective review of 6 patients (2007-2025) and an expanded literature review of 94 patients with F-NMH or F-NM.
- Analysis of medical records, electrodiagnostic studies, muscle histopathology, and magnetic resonance imaging (MRI).
Main Results:
- Unilateral calf hypertrophy was most common, followed by trapezius and biceps brachii.
- Electrodiagnostics revealed mixed denervation/reinnervation changes; 50% showed complex repetitive discharges.
- Muscle biopsies showed mixed myopathic/neurogenic changes; 39% had inflammation, which did not affect prognosis.
Conclusions:
- F-NMH is a rare, non-progressive, benign reaction to peripheral nerve injury with unknown multifactorial causes.
- Muscle inflammation is not consistently found and appears to be an epiphenomenon.
- Spontaneous improvement occurs, and treatments like botulinum toxin and prednisone are effective.
Related Concept Videos
Myasthenia Gravis: Overview and Treatment
1.9K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.9K
Satellite Stem Cells and Muscular Dystrophy
2.0K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.0K
Disorders of the Skeletal Muscle
1.1K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
1.1K
Myasthenia Gravis: Diagnostic Tests
1.3K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.3K
Muscle Contraction
6.9K
In skeletal muscles, acetylcholine is released by nerve terminals at the motor endplate—the point of synaptic communication between motor neurons and muscle fibers. The binding of acetylcholine to its receptors on the sarcolemma allows entry of sodium ions into the cell and triggers an action potential in the muscle cell. Thus, electrical signals from the brain are transmitted to the muscle. Subsequently, the enzyme acetylcholinesterase breaks down acetylcholine to prevent excessive...
6.9K
Chemical Synapses
9.1K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
9.1K

